FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1679-1680 June 1, 2000 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Sildenafil is a potent inhibitor of guanosine 3',5'-cyclic monophosphate (cGMP)–specific phosphodiesterase.^1,2 It is being used increasingly by male kidney-transplant recipients for erectile dysfunction,^3,4 but its effects on the grafted kidney have not, to our knowledge, been examined.

We performed clearance studies 18 to 126 months after renal transplantation in 10 men (age range, 43 to 72 years) who were receiving azathioprine, prednisone, and cyclosporine. All 10 men had impotence according to the International Index of Erectile Function. During the studies, an iterative oral water-loading regimen (0.5 liter per hour) was used to achieve stable diuresis, and the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Bouley, R., Pastor-Soler, N., Cohen, O., McLaughlin, M., Breton, S., Brown, D. (2005). Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am. J. Physiol. Renal Physiol. 288: F1103-F1112 [Abstract] [Full Text]